Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Xenon Pharmaceuticals Inc (XENE)

$16.37 0.34 (2.03%)

11:01 EST XENE Stock Quote Delayed 15 Minutes

Volume:

Previous Close $16.71

Market Cap 288.31M

PE Ratio -10.91

EPS -1.5

Volume (Avg. Vol.) 59,688

Day's Range 16.15 - 16.93

52-Week Range 7.58 - 18.45

Dividend & Yield N/A (N/A)

XENE Stock Predictions, Articles, and Xenon Pharmaceuticals Inc News

From InvestorPlace
From the Web

Xenon Pharmaceuticals Inc (XENE) Plunges on Acne Drug Flop

By William White, InvestorPlace Writer Mar 24, 2017

Xenon Pharmaceuticals (XENE) stock was falling hard on Friday following results from a recent study of its acne drug XEN801.

The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

From Benzinga Feb 14, 2020

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex...

Best & Worst Performing Small Cap Stocks for February 12, 2020

From StockNews.com Feb 12, 2020

CAN – CAN leads the way today as the best performing small cap stock, closing up 82.73%.

Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

From Zacks Investment Research Feb 6, 2020

The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.

Should You Be Concerned About Xenon Pharmaceuticals Inc.’s (NASDAQ:XENE) Historical Volatility?

From Simply Wall St Feb 6, 2020

If you’re interested in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-you-be-concerned-about-xenon-pharmaceuticals-inc-s-nasdaqxene-historical-volatility-2/">Read More...</a></div>

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

From Zacks Investment Research Feb 4, 2020

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.

Top Ranked Momentum Stocks to Buy for February 4th

From Zacks Investment Research Feb 4, 2020

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 4th

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy